STING1 and glioma: Compared with the free SR717 and PBS groups, IL-2 levels in the SR717@RGE-HFn NP treatment group were increased by 4.96- and 6.97-fold, respectively, suggesting that SR717 substantially improved the adaptive T cell response within the glioma TME via the STING pathway when delivered by RGE-HFn NPs (Fig. 6F).